PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Penn bioinformaticians are testing REALGAR, an application to simplify searches of GWAS, WGS, RNA-seq, and other test results for wet-lab researchers.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
The firm hopes its newly launched DxWound will improve pathogen detection in skin and soft tissue infections by including anaerobic and fungal microbes in its reports.
The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The ThromboSeq test detected early-stage cancer with 81 percent accuracy and late-stage cancer with 88 percent accuracy.
Presenters highlighted early work that supports the push for a national, systematic effort to elucidate progression from precancerous states to clinical malignancy.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.